2025 NHMRC Project "Engineered Drugs That Specifically Inhibit Clotting " at RMIT and Monash University

Myocardial infarction (heart attack) and stroke remain leading causes of global death and disability. This PhD project is part of a large NHMRC-funded initiative aiming to develop engineered drugs that specifically inhibit clotting in specific sites, and eliminating the risk of major bleeding complications associated with conventional anticoagulant therapies. By integrating computational modelling, biomimetic microfluidic, and advanced data analysis, this research aims to deliver innovative solutions to global health challenges.

Table of Content

• Summary
• Benefits
• Requirments
• Application Deadline
• How To Apply

Summary

• Application DeadlineNovember 30, 2025
• Value$41,000 per year tax free
• Study LevelPhD
• SponsorAustralian Government
• City to studyVictoria, Victoria
• School to studyMonash University, Royal Melbourne Institute of Technology
• Eligible CountryAll Countries

Benefits

• $41,000 per year tax free.

Requirements

• This project is suited to engineering students with experience or a strong interest in at least one of the following areas:
  • Fluid dynamics
  • Microfabrication
  • Machine learning and Al
  • Physiology.

• Applicant should have interest in fluid mechanics, microfabrication, Al and a first class honours degree or equivalent.

Application Deadline

How To Apply

For further details, please contact:

• Prof Gary Rosengarten: [email protected]
• Dr Josie Carberry: [email protected]
• Prof Christoph Hagemeyer: [email protected]

To apply, please send your CV and academic transcript to one of the above.

For more information, kindly visit RMIT University scholarship webpage.